GET DAILY SIGNALSPrestige Consumer Healthcare (PBH) Revenue Rises +22.7% but Stock Drops -16.8% After Guidance Cut
Key Takeaways
- Quarterly revenue rose 22.7% year over year to $336.3 million, lifted by the first full quarter of ownership of the Breathe Right and LaCorium acquisitions.
- Adjusted diluted earnings per share (EPS) climbed about 6% to $1.13, edging past consensus estimates near $1.07.
- Organic revenue, which excludes acquisitions and foreign currency, declined 1.6% on order timing and softer Clear Eyes sales.
- Reported (GAAP) diluted EPS fell to $0.53 from $0.86 a year ago, weighed down by acquisition-related costs and higher interest expense.
- Management lowered its fiscal 2027 outlook, citing renewed Clear Eyes production variability at the Pillar5 facility.
Earnings Context and Why It Matters
Prestige Consumer Healthcare operates on a fiscal year ending March 31, so its second quarter covered the July-to-September 2026 period. This report carried outsized importance for two reasons. First, it represented the first full quarter of ownership for the Breathe Right and LaCorium acquisitions, giving investors their clearest read yet on how those deals are translating into revenue and profit. Second, the quarter tested whether the company's core over-the-counter (OTC) healthcare portfolio could grow on its own, independent of deal-making. The recurring challenge of Clear Eyes supply disruptions at the Pillar5 production site has kept that eye-care brand in the spotlight, making this report a key gauge of both acquisition execution and operational recovery.
Reported Results
Prestige Consumer Healthcare reported second-quarter fiscal 2027 revenue of $336.3 million, up 22.7% from $274.1 million in the prior-year period. The Breathe Right and LaCorium acquisitions contributed $65.1 million to quarterly revenue, while organic revenue declined 1.6% versus the prior year, reflecting order timing pulled into the first quarter and weaker Clear Eyes sales. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Adjusted diluted EPS increased about 6% to $1.13, compared with $1.07 a year earlier and above consensus estimates near $1.07. On a reported basis under GAAP (Generally Accepted Accounting Principles), diluted EPS fell to $0.53 from $0.86, as the company absorbed inventory step-up amortization, Pillar5 remediation and idle-capacity costs, and a roughly threefold increase in interest expense tied to acquisition debt.
Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin reached approximately 33.6%, while adjusted gross margin improved to 57.7% from 55.3%. For the first half, revenue rose 15.0% to $602.0 million and adjusted diluted EPS reached $2.11, up from $2.02.
Notably, management reduced its fiscal 2027 guidance. The company now expects revenue of $1.28 billion to $1.29 billion (down from $1.29 billion to $1.315 billion), adjusted diluted EPS of $4.48 to $4.55 (down from $4.55 to $4.65), organic growth roughly flat (down from 1% to 3%), and adjusted free cash flow of at least $265 million. The revision was driven by renewed production variability for Clear Eyes at Pillar5, which began in late September and continued into October.
Market Reaction and Investor Sentiment
The market's response was decisively negative despite a headline beat. PBH shares fell roughly 16.8% on the day of the report, dropping near the stock's 52-week low and erasing a pre-earnings rally from the prior session. Investors focused less on the acquisition-driven revenue growth and more on the guidance cut, which signaled that the Clear Eyes recovery timeline has slipped again. The contrast between strong adjusted results and weaker organic performance added to the skepticism, as the base business swung from growth in the first quarter to a decline in the second. With the eye-care supply issue now extending into fiscal 2028, sentiment has shifted toward caution on the company's near-term growth trajectory.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether Pillar5 can finally stabilize Clear Eyes production. Management has pushed the brand's full recovery into fiscal 2028 and now expects Clear Eyes to generate less than $20 million in revenue this year. Progress at the facility, including site-management changes and any build-up of safety stock, will be a central factor in the next several quarters.
Beyond Clear Eyes, the core portfolio appears resilient. Management noted that organic growth excluding Clear Eyes is running near 2%, supported by brands such as Dramamine, TheraTears, Compound W, and Hydralyte. The successful integration of Breathe Right and LaCorium, both described as on track, remains a key growth driver heading into fiscal 2028.
Financial discipline will also be in focus. Net debt stood at approximately $2.1 billion at quarter-end, and the company has signaled that it intends to use its industry-leading free cash flow to reduce leverage over the remainder of the fiscal year. With adjusted free cash flow guidance now at least $265 million and interest expense projected near $104 million, deleveraging progress will matter as much as top-line growth.
Finally, management reiterated its medium-term targets of roughly 10% annual revenue growth and about 8% annual EPS growth, but those ambitions now hinge on stabilizing eye-care supply and executing on the recent acquisitions.
Using AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener can help investors quickly compare names like PBH against peers on fundamentals and technical signals. I often run similar screens when reviewing quarterly results to see how a stock stacks up on volatility, trends, or industry positioning before forming a fuller picture. This approach keeps the process efficient without replacing core fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PBH in upward trend: price rose above 50-day moving average on October 29, 2026
PBH moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on PBH as a result. In 53 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for PBH just turned positive on October 29, 2026. Looking at past instances where PBH's MACD turned positive, the stock continued to rise in 22 of 37 cases over the following month. The odds of a continued upward trend are 59%.
The 10-day moving average for PBH crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +2.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBH advanced for three days, in 167 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 52%.
The Aroon Indicator entered an Uptrend today. In 124 of 229 cases where PBH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
PBH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. PBH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.095) is normal, around the industry mean (7.659). P/E Ratio (12.380) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (1.482) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.042) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which markets over-the-counter drugs, household cleaning and personal care products
Industry PharmaceuticalsGeneric
Advertisement